pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›INGREZZA SPRINKLE
drug · small molecule
save

INGREZZA SPRINKLE

updated 3mo ago
by $NBIX NEUROCRINE BIOSCIENCES INC🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval12 co-mentions · 4 sources
  • tagSmall Molecule6 co-mentions · 4 sources
  • drugVALBENAZINE TOSYLATE6 co-mentions · 4 sources
  • drugvalbenazine6 co-mentions · 4 sources
  • companyZydus Lifesciences Ltd2 co-mentions · 2 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for movement disorder and 1 investigational indication.

targets

Synaptic vesicular amine transporter

all catalysts(0)

nothing on the calendar yet

News(1)

  • Novo’s late-stage IL-6 stumble shakes inflammation space
    Novo Nordisk was banking on the inflammatory benefits of its investigational therapy ziltivekimab to improve cardiovascular outcomes. Last week’s Phase 3 failure dashed not just the Danish pharma’s…
    biospace · 8d ago
brand
INGREZZA SPRINKLE
trade names
Ingrezza, Ingrezza sprinkle
generic
VALBENAZINE TOSYLATE
MOA
12.1 Mechanism of Action The mechanism of action of valbenazine for the treatment of tardive dyskinesia and chorea in patients with Huntington’s disease is unclear, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
indication
1 INDICATIONS AND USAGE INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia [see Clinical Studies ( 14.1 )] . - chorea associated with Huntington’s disease [see Clinical Studies ( 14.2 )] . INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with: - tardive dyskinesia. ( 1 ) - chorea associated with Huntington’s disease. ( 1 )
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 54m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?